Advice
In the absence of a submission from the holder of the marketing authorisation
dexrazoxane (Cardioxane) is not recommended for use within NHSScotland for the prevention of chronic cumulative cardiotoxicity caused by doxorubicin or epirubicin use in advanced and/or metastatic cancer patients after previous anthracycline containing treatment.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice24KB (PDF)
Medicine details
- Medicine name:
- dexrazoxane (Cardioxane) 419/07
- SMC ID:
- 419/07
- Indication:
- for the prevention of chronic cumulative cardiotoxicity caused by doxorubicin or epirubicin use in advanced and/or metastatic cancer patients after previous anthracycline containing treatment
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 November 2007